Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.

Yihienew Mequanint BezabihAlemayehu BezabihEndalkachew AlamnehGregory M PetersonWoldesellassie Bezabhe

Published in: BMC infectious diseases (2021)

RAAS inhibitors did not increase the risk of mortality or severity of COVID-19. Differences in COVID-19 clinical outcomes between different class of antihypertensive drugs were likely due to the underlying comorbidities for which the antihypertensive drugs were prescribed, although adverse effects of drugs such as BBs could not be excluded.

Keyphrases

coronavirus disease
blood pressure
sars cov
respiratory syndrome coronavirus
angiotensin ii
angiotensin converting enzyme
hypertensive patients
cardiovascular events
risk factors
type diabetes
drug induced
emergency department